NO20083979L - Farmasoytisk sammensetning omfattende oseltamivirfosfat - Google Patents

Farmasoytisk sammensetning omfattende oseltamivirfosfat

Info

Publication number
NO20083979L
NO20083979L NO20083979A NO20083979A NO20083979L NO 20083979 L NO20083979 L NO 20083979L NO 20083979 A NO20083979 A NO 20083979A NO 20083979 A NO20083979 A NO 20083979A NO 20083979 L NO20083979 L NO 20083979L
Authority
NO
Norway
Prior art keywords
sugar
pharmaceutical composition
oseltamivir phosphate
weight
sugar alcohol
Prior art date
Application number
NO20083979A
Other languages
English (en)
Other versions
NO342112B1 (no
Inventor
Ryuji Kubota
Tomoaki Ohta
Tomoaki Hirayama
Hiroyuki Maeda
Christian Volland
Hans-Guenter Kaestle
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38437365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083979(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20083979L publication Critical patent/NO20083979L/no
Publication of NO342112B1 publication Critical patent/NO342112B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En farmasøytisk sammensetning omfattende minst en eksipient valgt fra et sukker og en sukkeralkohol som hver har et likevekts-fuktighetsinnhold på 1 vekt% eller lavere ved 25°C og 70% relativ fuktighet og oseltamivirfosfat, hvori sukkeret eller sukkeralkoholen inneholder glukose og mannose som urenheter hver i en mengde på 0,01 vekt% eller mindre i forhold til vekten av sukkeret eller sukkeralkoholen.
NO20083979A 2006-02-20 2008-09-18 Farmasøytisk sammensetning omfattende oseltamivirfosfat og anvendelse derav NO342112B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006042178 2006-02-20
PCT/JP2007/053081 WO2007097325A1 (ja) 2006-02-20 2007-02-20 リン酸オセルタミビル含有医薬組成物

Publications (2)

Publication Number Publication Date
NO20083979L true NO20083979L (no) 2008-11-11
NO342112B1 NO342112B1 (no) 2018-03-26

Family

ID=38437365

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083979A NO342112B1 (no) 2006-02-20 2008-09-18 Farmasøytisk sammensetning omfattende oseltamivirfosfat og anvendelse derav

Country Status (15)

Country Link
US (1) US9012499B2 (no)
EP (1) EP1987825B1 (no)
JP (1) JP5255429B2 (no)
KR (1) KR20080097468A (no)
CN (1) CN101389323B (no)
AU (1) AU2007218733B2 (no)
BR (1) BRPI0708108B1 (no)
CA (1) CA2642952C (no)
HK (1) HK1126971A1 (no)
IL (1) IL193372A (no)
NO (1) NO342112B1 (no)
RU (1) RU2008137613A (no)
SG (1) SG183583A1 (no)
WO (1) WO2007097325A1 (no)
ZA (1) ZA200806356B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
CN102316874B (zh) * 2008-12-17 2017-05-03 佐藤制药株式会社 崩解片剂
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
CN102166206B (zh) * 2011-02-12 2012-10-10 李春娟 液体的磷酸奥司他韦组合物
RU2633085C2 (ru) * 2014-05-20 2017-10-11 Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" Противовирусное лекарственное средство в виде капсул и способ его получения
KR20160002177A (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 오셀타미비어 유리염기를 포함하는 약학 조성물
KR20160038837A (ko) * 2014-09-30 2016-04-07 한미약품 주식회사 오셀타미비어 함유 과립, 그 과립을 포함하는 캡슐제, 및 이들의 제조방법
BR112017011623A2 (pt) * 2014-12-01 2018-03-06 Lupin Atlantis Holdings Sa composições farmacêuticas e processo para a preparação de uma composição
KR20160117070A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법
KR101953294B1 (ko) 2018-04-12 2019-03-04 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292451A (en) * 1978-03-30 1981-09-29 Ici Americas Inc. High mannitol process (alkaline hydrogenation in presence of alkali metal carbonate)
JPH0813737B2 (ja) * 1986-12-19 1996-02-14 杏林製薬株式会社 シロツプ剤
JPH0723304B2 (ja) * 1988-04-19 1995-03-15 三菱化学株式会社 薬剤成分固定化組成物
JP4165878B2 (ja) * 1993-06-03 2008-10-15 株式会社林原生物化学研究所 トレハロース遊離酵素とその製造方法並びに用途
JPH0827033A (ja) * 1994-07-14 1996-01-30 Nikken Chem Co Ltd エリスリトール含有固形剤
CN1185223C (zh) 1995-02-27 2005-01-19 吉里德科学公司 新颖化合物,其合成方法及治疗用途
EP0879048B2 (en) * 1996-02-09 2009-07-29 Quadrant Drug Delivery Limited Method for making tablets using trehalose
KR20000005486A (ko) 1996-04-16 2000-01-25 빌프리더 하이더 D-만니톨 및 그의 제법
JP3126683B2 (ja) * 1996-04-16 2001-01-22 武田薬品工業株式会社 Ｄ−マンニトールおよびその製造法
WO1998007685A1 (en) 1996-08-23 1998-02-26 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
JPH1135486A (ja) 1997-07-23 1999-02-09 Lion Corp 薬用固形製剤
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
JP3228335B2 (ja) 1998-02-26 2001-11-12 萬有製薬株式会社 口腔内崩壊型組成物及びその製造方法
AU2640599A (en) 1998-02-26 1999-09-15 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US20040202714A1 (en) * 1999-10-12 2004-10-14 Daiichi Suntory Pharma Co., Ltd. Oral pharmaceutical composition
PL203804B1 (pl) 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
JP5100391B2 (ja) * 2005-10-05 2012-12-19 京都薬品工業株式会社 経口用組成物
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets

Also Published As

Publication number Publication date
AU2007218733B2 (en) 2012-11-15
CN101389323B (zh) 2013-08-21
SG183583A1 (en) 2012-09-27
WO2007097325A1 (ja) 2007-08-30
IL193372A0 (en) 2009-09-22
KR20080097468A (ko) 2008-11-05
AU2007218733A1 (en) 2007-08-30
BRPI0708108B1 (pt) 2021-12-14
IL193372A (en) 2015-09-24
US20100222427A1 (en) 2010-09-02
CA2642952C (en) 2014-09-02
BRPI0708108A2 (pt) 2011-05-17
HK1126971A1 (en) 2009-09-18
EP1987825A1 (en) 2008-11-05
CA2642952A1 (en) 2007-08-30
US9012499B2 (en) 2015-04-21
ZA200806356B (en) 2009-11-25
CN101389323A (zh) 2009-03-18
EP1987825B1 (en) 2018-09-05
NO342112B1 (no) 2018-03-26
EP1987825A4 (en) 2012-10-17
JP5255429B2 (ja) 2013-08-07
JPWO2007097325A1 (ja) 2009-07-16
RU2008137613A (ru) 2010-03-27

Similar Documents

Publication Publication Date Title
NO20083979L (no) Farmasoytisk sammensetning omfattende oseltamivirfosfat
Gidaro et al. Kaempferol as selective human MAO-A inhibitor: analytical detection in calabrian red wines, biological and molecular modeling studies
WO2009088572A3 (en) Method of treating erythropoietin hyporesponsive anemias
CL2008000329A1 (es) Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.
WO2007122581A3 (en) Compositions and kits of phenylephrine
NO20071610L (no) Immunogen sammensetning
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20064328L (no) Isoquinolinderivater og fremgangsmater for anvendelse derav
WO2007113327A3 (en) Fungicide n-cyclopropyl-sulfonylamide derivatives
WO2009115557A3 (en) Fungicide hydroximoyl-tetrazole derivatives
BRPI0518889A2 (pt) plantas de cana-de-aÇécar com um conteédo de carboidrato de armazenamento aumentado
EA201391651A1 (ru) Сокристаллы l-пролина и лимонной кислоты (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфенил)тиофен-2-ил)метил)-4-метилфенил)-6-(гидроксиметил)тетрагидро-2h-пиран-3,4,5-триол
NO20076355L (no) Dengue serotype 1 attenuert stamme
FR2927335B1 (fr) Hydrolysat de proteines de poissons presentant une activite satietogene, compositions nutraceutiques et pharmacologiques comprenant un tel hydrolysat et procede d'obtention
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2007103785A3 (en) Plant-derived protein compositions
BRPI0416713A (pt) métodos de produção de uma planta e de uma célula vegetal resistentes a um fungo fitopatogênico, célula vegetal e planta resistentes a um fungo fitopatogênico, arroz, tabaco, métodos para a identificação de um gene essencial ao desenvolvimento ou à patogenicidade de um fungo fitopatogênico, método para inibir a expressão de um gene de fungo, métodos para reduzir a expressão de gene de fungo e uso de um constructo
ATE485261T1 (de) Salicylsäurederivate
BR112012013922A2 (pt) composição de grão inteiro hidrolisado
ATE423548T1 (de) Pharmazeutische zusammensetzung
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
NO20080515L (no) Aktiv fraksjon fra et polart losningsmiddelekstrakt fra lates fra euphoribiaceae-plantene
Rubiolo et al. Chemical and biomolecular characterization of Artemisia umbelliformis Lam., an important ingredient of the alpine liqueur “Genepì”
IN2015DN03104A (no)